Skip to Content
Merck
  • Stromal SLIT2 impacts on pancreatic cancer-associated neural remodeling.

Stromal SLIT2 impacts on pancreatic cancer-associated neural remodeling.

Cell death & disease (2015-01-16)
V Secq, J Leca, C Bressy, F Guillaumond, P Skrobuk, J Nigri, S Lac, M-N Lavaut, T-T Bui, A K Thakur, N Callizot, R Steinschneider, P Berthezene, N Dusetti, M Ouaissi, V Moutardier, E Calvo, C Bousquet, S Garcia, G Bidaut, S Vasseur, J L Iovanna, R Tomasini
ABSTRACT

Pancreatic ductal adenocarcinoma (PDA) is a critical health issue in the field of cancer, with few therapeutic options. Evidence supports an implication of the intratumoral microenvironment (stroma) on PDA progression. However, its contribution to the role of neuroplastic changes within the pathophysiology and clinical course of PDA, through tumor recurrence and neuropathic pain, remains unknown, neglecting a putative, therapeutic window. Here, we report that the intratumoral microenvironment is a mediator of PDA-associated neural remodeling (PANR), and we highlight factors such as 'SLIT2' (an axon guidance molecule), which is expressed by cancer-associated fibroblasts (CAFs), that impact on neuroplastic changes in human PDA. We showed that 'CAF-secreted SLIT2' increases neurite outgrowth from dorsal root ganglia neurons as well as from Schwann cell migration/proliferation by modulating N-cadherin/β-catenin signaling. Importantly, SLIT2/ROBO signaling inhibition disrupts this stromal/neural connection. Finally, we revealed that SLIT2 expression and CAFs are correlated with neural remodeling within human and mouse PDA. All together, our data demonstrate the implication of CAFs, through the secretion of axon guidance molecule, in PANR. Furthermore, it provides rationale to investigate the disruption of the stromal/neural compartment connection with SLIT2/ROBO inhibitors for the treatment of pancreatic cancer recurrence and pain.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
SLIT-2-N human, recombinant, expressed in HEK 293 cells, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Sigma-Aldrich
MISSION® esiRNA, targeting human SLIT2